|1.||Iles, Ray K: 3 articles (01/2014 - 08/2002)|
|2.||Butler, Stephen A: 2 articles (01/2014 - 12/2003)|
|3.||Chang, Jun: 2 articles (08/2013 - 12/2012)|
|4.||Oevermann, Anna: 2 articles (06/2011 - 06/2007)|
|5.||Zurbriggen, Andreas: 2 articles (06/2011 - 06/2007)|
|6.||Seuberlich, Torsten: 2 articles (06/2011 - 06/2007)|
|7.||Berger, P: 2 articles (01/2007 - 08/2000)|
|8.||Suzuki, H: 2 articles (12/2001 - 01/2001)|
|9.||Okamoto, T: 2 articles (12/2001 - 01/2001)|
|10.||Matsuo, K: 2 articles (12/2001 - 01/2001)|
|1.||Vulvar Neoplasms (Vulvar Cancer)
|2.||Down Syndrome (Down's Syndrome)
04/01/1999 - "Initial studies by Cuckle et al. (1994) and Canick et al. (1995) indicated that beta-core fragment was an outstanding marker, detecting >80 per cent of Down syndrome cases. "
02/01/1999 - "Studies on beta core fragment (beta CF), the major urinary metabolite of hCG, have indicated that screening with beta CF and other markers measured in maternal urine might improve the detection of Down syndrome and provide a less expensive and simpler test. "
12/01/1997 - "In the present study, urinary total oestriol has been evaluated as a marker to use in combination with beta-core fragment in screening for Down syndrome pregnancies. "
10/01/1999 - "In this first reported direct comparison we consistently observed higher sensitivity values for screening with urinary levels of beta-core fragment than for serum triple screen, suggesting an equivalent or superior Down syndrome screening performance for the urinary analyte. "
10/01/1999 - "Urinary concentration of beta-core fragment had a 61.9% detection rate with a 4.9% false-positive rate for Down syndrome, whereas the values for the triple screen were 57. "
01/12/2001 - "The present study was undertaken to investigate whether hCG beta-core fragment (hCGbeta cf) was directly produced by cancer cells. "
08/01/1999 - "In the first week (during therapy) beta-core fragment levels increased (12 fmol/ml), and in the following weeks (after therapy) levels regressed to 1.2 fmol/ml. Urine beta-core fragment may be a useful tumor maker when serum hCG levels are near to or below the limit of detection."
04/01/1998 - "Moreover, we correlated histological differentiation and tumor stages with marker expression and, finally, evaluated a potential tumor origin of hCGbeta core-fragment (hCGbetacf). "
01/01/1997 - "In this report, we evaluate the stability of urinary gonadotropin peptide (UGP), an urinary tumor marker for trophoblastic malignancies, which is also promising for other types of cancer. "
07/01/1996 - "Urinary gonadotropin peptide in patients with cancer of digestive organs."
|4.||Trophoblastic Neoplasms (Trophoblastic Tumor)
04/01/1998 - "We analyzed immunoreactive hCG/hCGbeta (IR-beta) in the sera and urine of patients with trophoblastic diseases and non-trophoblastic tumors by using enzyme immunoassays (EIAs) specific for intact hCG, free hCG beta, and beta-core fragment of hCG (beta-CF). "
12/01/2001 - "The present study was undertaken to investigate whether human chorionic gonadotropin (hCG) beta-core fragment (hCG beta cf) was directly produced by gestational trophoblastic tumors. "
12/01/2001 - "Human chorionic gonadotropin (hCG) beta-core fragment is produced by degradation of hCG or free hCG beta in gestational trophoblastic tumors: a possible marker for early detection of persistent postmolar gestational trophoblastic disease."
|5.||Female Genital Diseases
09/01/1994 - "Urinary gonadotropin peptide (UGP) was measured in 866 urines from normal women and women with benign and malignant gynecologic disease using the Triton UGP enzyme immunoassay. "
11/01/1999 - "The objective of this study was to assess 1) the value of urinary gonadotropin peptide (UGP) as a single test and the combination of UGP with CA 125 as a diagnostic test in predicting the benign or malignant origin of gynecologic disease, 2) the influence of surgical removal of the tumor on the levels of UGP and CA 125, 3) the influence of the urinary concentration on the UGP levels in relation to the test results. "
|1.||squamous cell carcinoma-related antigen
|2.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|3.||Human beta Subunit Chorionic Gonadotropin
|9.||GTP-Binding Proteins (G-Protein)